Does low-dose daily aspirin really reduce cardiovascular risk in diabetes?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Recent trial data don’t solidly back guidelines encouraging use of aspirin for primary prevention of cardiovascular disease (CVD) in adults with diabetes and at increased CVD risk.
Systematic review and meta-analysis of randomized controlled trials of aspirin compared with placebo (or no treatment) in patients with diabetes with no history of cardiovascular disease.
A total of 10 randomized trials were included.
There was a modestly significant reduction in risk of major adverse cardiovascular events (MACE) with aspirin therapy compared with placebo or no treatment, but significance was lost with the exclusion of 1 trial that included few patients with previous CVD.
The effect of aspirin on major adverse cardiovascular events appeared to differ by baseline CVD risk, medication compliance, and sex (P for interaction for all .05).
Aspirin did not significantly reduce the overall risks of myocardial infarction (MI), coronary heart disease, stroke, ...